SCHEMBL2804156

SCHEMBL2804156

COc1cc(C(=O)O)ccc1OCc1ccc(C)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 3/20 0.78
RXRA P19793 1/20 0.65
TSHR P16473 1/20 0.64
NPC1 O15118 4/20 0.63
RAB9A P51151 4/20 0.63
SMN1; SMN2 Q16637 3/20 0.62
PAX8 Q06710 2/20 0.62
POLB P06746 2/20 0.62
TP53 P04637 1/20 0.62
KLF5 Q13887 1/20 0.62
HIF1A Q16665 1/20 0.62
HPGD P15428 1/20 0.61
CA12 O43570 1/20 0.61
CA1 P00915 1/20 0.61
CA2 P00918 1/20 0.61
CA4 P22748 1/20 0.61
CA6 P23280 1/20 0.61
CA7 P43166 1/20 0.61
TPMT P51580 1/20 0.61
CA9 Q16790 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9360159 0.89 MRGPRX4 (0.78) MRGPRX4RXRATSHRNPC1RAB9A
SCHEMBL242563 0.88 MRGPRX4 (0.77) MRGPRX4RXRATSHRNPC1RAB9A
SCHEMBL5307725 0.87 MRGPRX4 (0.76) MRGPRX4RXRATSHRNPC1RAB9A
SCHEMBL2801658 0.87 MAPT (0.72) MRGPRX4RXRANPC1RAB9ASMN1; SMN2
SCHEMBL14906965 0.87 MRGPRX4 (1.00) MRGPRX4RXRATSHRNPC1RAB9A
SCHEMBL11277266 0.87 MRGPRX4 (0.75) MRGPRX4RXRATSHRNPC1RAB9A
SCHEMBL7372360 0.85 NPC1 (0.68) MRGPRX4RXRATSHRNPC1RAB9A
SCHEMBL2815273 0.84 MRGPRX4 (0.71) MRGPRX4RXRATSHRNPC1RAB9A
SCHEMBL12431984 0.84 POLB (0.60) MRGPRX4RXRANPC1RAB9ASMN1; SMN2
SCHEMBL7469360 0.84 MRGPRX4 (0.71) MRGPRX4RXRATSHRNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010132016-A1 BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION ASTRAZENECA AB (SE) 2010-11-18 WO disclosed
WO-2010132016-A1 BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION ASTRAZENECA AB (SE) 2010-11-18 WO disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy PTGER1, SULT2A1, SULT1E1 MRGPRX4 803/4885RXRA 1047/4885TSHR 583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.